Research in the oncology field is abundant, such as the correlation between GCNT1 expression and disease aggressiveness in prostate cancer [31]; GCNT2 as a biomarker and novel therapeutic target for melanoma [32], and its induction of epithelial-mesenchymal transition in colorectal and esophageal cancer [33, 34]; GCNT3 is mainly associated with the prognosis of colon cancer but also relates to pancreatic cancer and hepatocellular carcinoma [35]; GCNT4 is closely related to gastric cancer [36]. This evidence concerns the gene GCNT1 and prostate cancer.